Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

PartnershiplacutamabPositive

AI Analysis

Summary

Sobi and Innate Pharma announced a strategic partnership to license lacutamab for T-cell lymphoma, enabling initiation of the TELLOMAK-3 confirmatory trial. The collaboration combines both companies' capabilities to advance the investigational treatment.

Clinical Trial Data

Importance:7/10

Sentiment:

0.60

partnershiplicensinglacutamabT-cell lymphomaTELLOMAK-3

Related Companies

$SOBI.ST $IPHA

Read the original article

Published by PR Newswire Biotech on August 10, 2026 6:36 AM

Read Original